Nuwiq (Human coagulation factor VIII [rDNA], simoctocog alfa) for Hemophilia

Overview
Nuwiq is approved by the Food and Drug Administration (FDA) to treat and prevent bleeding episodes in children and adults with hemophilia A (congenital factor VIII deficiency). The technical name of Nuwiq is Human coagulation factor VIII (rDNA), simoctocog alfa.

Nuwiq is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.

How do I take it?
Prescribing information states that Nuwiq is given as an intravenous injection.

Nuwiq comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Nuwiq does not list common side effects. Less commonly, Nuwiq may cause headache, dry mouth, vertigo, pins-and-needles sensations, back pain, and pain at injection site.

Rare but serious side effects listed for Nuwiq include life-threatening hypersensitivity reactions, complications involving the catheter of the central venous access device (CVAD), and the development of inhibitors.

For more details about this treatment, visit:

Nuwiq.com
http://www.nuwiqusa.com/

Treatment of Hemophilia – Hemophilia Federation of America
http://www.hemophiliafed.org/bleeding-disorders...